<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">THIOPENTAL SODIUM <img border="0" src="../images/pr.gif"/></span><br/>(thye-oh-pen'tal)<br/><span class="topboxtradename">Pentothal<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">general anesthetic</span>; <span class="classification">sedative-hypnotic</span>; <span class="classification">barbiturate</span><br/><b>Pregnancy Category: </b>C<br/><b>Controlled Substance: </b>Schedule III<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>20 mg/mL, 25 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Ultrashort-acting barbiturate; induces brief general anesthesia without analgesia by depression of CNS. Loss of consciousness
         is rapid. Reduction in cardiac output and peripheral vasodilation frequently accompany anesthesia. Rapid redistribution of
         agent out of brain reduces anesthesia level and increases reflex airway hyperactivity to mechanical stimulation. Muscle relaxation
         is slight, and reflexes are poorly controlled.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Since analgesia is slight, thiopental is seldom used alone except for brief minor procedures. It does not act as an analgesic
         when given as an analgesic.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>To induce hypnosis and anesthesia prior to or as supplement to other anesthetic agents or as sole agent for brief (15-min)
         operative procedures. Also used as an anticonvulsant and sedative-hypnotic and for narcoanalysis and narcosynthesis in psychiatric
         disorders.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to barbiturates; history of paradoxic excitation; absence of suitable veins for IV administration; status
         asthmaticus; acute intermittent or other hepatic porphyrias. Safety during pregnancy (category C), lactation, or children
         is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Coronary artery disease, hypotension, shock; conditions that may potentiate or prolong hypnotic effect including excessive
         premedication, liver or kidney dysfunction, myxedema, Addison's disease, severe anemia, increased BUN; increased intracranial
         pressure; myasthenia gravis; asthma and other respiratory diseases.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Induction</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV Test Dose</span> 2575 mg, then 5075 mg at 2040 sec intervals, an additional 50 mg may be given if needed<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> 35 mg/kg initially, followed by 1 mg/kg if needed<br/><span class="rdage">Infant:</span> <span class="rdroute">IV</span> 58 mg/kg<br/><span class="rdage">Neonate:</span> <span class="rdroute">IV</span> 34 mg/kg<br/><br/><span class="indicationtitle">Convulsions</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 75125 mg<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> 23 mg/kg<br/><br/><span class="indicationtitle">Narcoanalysis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 100 mg/min until confusion occurs<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<p>
         			Note: Verify correct IV concentration and rate of infusion to neonates, infants, children with physician.
         		
      </p>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p>Test dose: May be given to assess unusual sensitivity to drug. Following administration, observe patient for at least 1 min
                  for unexpected deep anesthesia or respiratory depression.
               </p>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Reconstitute each 500 mg of powder by adding at least 20 mL of sterile water for injection to yield a 2.5% solution (25
                  mg/1 mL). Add 20 mL of reconstituted solution to at least 100 mL of NS or D5W. Prepare solution freshly and use promptly.
                  If a precipitate is present, discard solution. Unused portions should be discarded within 24 h.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Infuse each 25 mg over 1 min or more. Do not infuse solution with a concentration 
               </p><p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>Dextrose Ringer's lactate,</b>
<b>10% dextrose,</b>
<b>amikacin,</b>
<b>benzquinamide,</b>
<b>cephapirin,</b>
<b>chlorpromazine,</b>
<b>codeine phosphate,</b>
<b>dimenhydrinate,</b>
<b>diphenhydramine,</b>
<b>doxapram,</b>
<b>ephedrine,</b>
<b>fibrinolysin,</b>
<b>glycopyrrolate,</b>
<b>hydromorphone,</b>
<b>insulin,</b>
<b>levorphanol,</b>
<b>meperidine,</b>
<b>metaraminol,</b>
<b>methadone,</b>
<b>morphine,</b>
<b>norepinephrine,</b>
<b>penicillin G,</b>
<b>prochlorperazine,</b>
<b>promazine,</b>
<b>promethazine,</b>
<b>sodium bicarbonate,</b>
<b>succinylcholine,</b>
<b>tetracycline.</b>
<span class="incompattype">Y-site:</span>
<b>Alfentanil,</b>
<b>ascorbic acid,</b>
<b>atracurium,</b>
<b>atropine,</b>
<b>cisatracurium,</b>
<b>diltiazem,</b>
<b>dobutamine,</b>
<b>dopamine,</b>
<b>ephedrine,</b>
<b>epinephrine,</b>
<b>furosemide,</b>
<b>hydromorphone,</b>
<b>labetalol,</b>
<b>lidocaine,</b>
<b>lorazepam,</b>
<b>midazolam,</b>
<b>morphine,</b>
<b>nicardipine,</b>
<b>norepinephrine,</b>
<b>pancuronium,</b>
<b>phenylephrine,</b>
<b>succinylcholine,</b>
<b>sufentanil,</b>
<b>vecuronium.</b>
</p>
<ul>
<li>Consult physician if intraarterial injection or extravasation occurs. The site will require particular attention to prevent
                     arteritis, neuritis, and skin slough. An intraarterial injection usually causes extreme pain before patient loses consciousness.
                  </li>
</ul>
</td>
</tr>
</table>
<ul>
<li>Store at 15°30° C (59°86° F). Avoid excessive heat; protect from freezing.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, retrograde amnesia, emergence delirium, prolonged somnolence and recovery. <span class="typehead">CV:</span> Myocardial depression, arrhythmias, <span class="speceff-life">circulatory depression</span>. <span class="typehead">GI:</span> Nausea, vomiting, regurgitation of gastric contents, rectal irritation, cramping, rectal bleeding, diarrhea. <span class="typehead">Respiratory:</span>
<span class="speceff-life">Respiratory depression with apnea</span>; hiccups, sneezing, coughing, bronchospasm, <span class="speceff-life">laryngospasm</span>. <span class="typehead">Body as a Whole:</span> Hypersensitivity reactions, <span class="speceff-life">anaphylaxis</span> (rare), hypothermia, thrombosis and sloughing (with extravasation); salivation, shivering, skeletal muscle hyperactivity. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>
<span class="alt">Thiopental</span> may cause decrease in <span class="alt">I<sup>123</sup>
</span>
<i>and</i>
<span class="alt">I<sup>131</sup> thyroidal uptake</span> test results.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">cns depressants</span> potentiate CNS and respiratory depression. <span class="classification">phenothiazines</span> increase risk of hypotension. <b>Probenecid</b> may prolong anesthesia. <span class="typehead">Herbal:</span>
<b>Kava-kava,</b>
<b>valerian</b> may potentiate sedation. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead"> Onset:</span>  3060 sec. <span class="typehead">Duration:</span> 1030 min. <span class="typehead">Distribution:</span> Distributed into muscle and liver; crosses placenta. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 12 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor vital signs q35min before, during, and after anesthetic administration until recovery and into postoperative
            period, if necessary.
         </li>
<li>Report increases in pulse rate or drop in blood pressure. Hypovolemia, cranial trauma, or premedication with opioids increases
            potential for apnea and symptoms of myocardial depression (decreased cardiac output and arterial pressure).
         </li>
<li>Shivering, excitement, muscle twitching may develop during recovery period if patient is in pain.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Onset of drug effect is rapid, with loss of consciousness within 3060 sec.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>